FDA Grants Expanded Approval for Illuccix in Patient Selection for Pre-Taxane Radioligand Therapy
The additional indication for the preparation kit of gallium Ga-68 gozetotide may facilitate earlier use of PSMA-targeted treatment for men with prostate cancer.
The Food and Drug Administration (FDA) has approved a third indication for Illuccix, a preparation kit for gallium Ga-68 gozetotide, which enables use for prostate cancer (PCa) patients being considered for pre-taxane radioligand therapy.
Estimating that the new indication may increase the use of Illuccix by up to 20,000 additional PSMA PET scans a year, Telix Pharmaceuticals, the manufacturer of Illuccix, suggested that expand access to PSMA PET imaging could lead to earlier treatment intervention for men with PCa.
“It is pleasing to see the ability to use gallium-68 PSMA-PET for patient selection expanded. This empowers clinicians to make more informed, personalized decisions earlier in the disease course and access life-prolonging targeted radionuclide therapy for more patients with prostate cancer,” noted Scott T. Tagawa, M.D., a genitourinary oncologist and professor of medicine and urology at Weill Cornell Medicine in New York City.
In combination with Ga 68 radiolabeling, Illuccix was previously indicated for PET imaging of PSMA-positive lesions in men with suspected PCa metastasis who are candidates for definitive therapy and those with suspected PCa recurrence due to elevated prostate-specific antigen (PSA) levels.
The Reading Room Podcast: Current Perspectives on the Updated Appropriate Use Criteria for Brain PET
March 18th 2025In a new podcast, Satoshi Minoshima, M.D., Ph.D., and James Williams, Ph.D., share their insights on the recently updated appropriate use criteria for amyloid PET and tau PET in patients with mild cognitive impairment.
FDA Grants Fast Track Designation to Emerging Agent for Brain PET Imaging
June 11th 2025Currently being evaluated in a phase 2b clinical trial, the 18F-RAD101 PET imaging agent garnered the FDA’s fast track designation for distinguishing between recurrent disease and treatment impact for brain metastases derived from solid tumors.
New PSMA PET Prep Product Now Available in the U.S.
June 11th 2025Offering an extended shelf life, the FDA-approved Gozellix, a preparation kit for gallium-68 (68Ga) gozetotide injection, is indicated for use in PSMA PET imaging of prostate cancer patients with suspected recurrence or metastasis.
Study: AI-Generated ADC Maps from MRI More Than Double Specificity in Prostate Cancer Detection
June 5th 2025Emerging research showed that AI-generated ADC mapping from MRI led to significant increases in accuracy, PPV and specificity in comparison to conventional ADC mapping while achieving a 93 percent sensitivity for PCa.
